Skip to main content

  • Transcatheter Mitral Valve Repair with MitraClip for Severe Mitral Regurgitation and Cardiogenic Shock During the COVID-19 Pandemic

    • Posted: 10/21/2020
    • Author:

      Kalyan R. Chitturi | Nadeen N. Faza | Stephen H. Little | Neal S. Kleiman | Michael J.Reardon | Sachin S. Goel

    • CRM2020

    Highlights

    • COVID-19 has strained health care systems worldwide, and elective structural heart interventions have been curtailed
    • Patients with severe mitral regurgitation (MR) and cardiogenic shock are high surgical risk and require timely intervention
    • We highlight effective triage of mitral interventions during the pandemic in accordance to the SCAI/ACC consensus

    Abstract

    Transcatheter mitral valve repair with MitraClip (Abbott) is largely an elective procedure. The ongoing coronavirus disease 2019 (COVID-19) pandemic has posed challenges to health care systems; in many cases elective interventions have been curtailed. Patients with severe mitral regurgitation (MR) and cardiogenic shock are high-risk surgical candidates and at risk of a poor outcome without intervention. The American College of Cardiology (ACC) and the Society of Coronary Angiography and Interventions (SCAI) recently proposed joint guidance on triage of structural heart disease (SHD) interventions during the COVID-19 pandemic. We present two illustrative cases of severe MR and cardiogenic shock that were successfully treated with MitraClip amidst the COVID-19 pandemic with good outcomes at short term follow-up.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details